Who are Low Dose Quillivant XR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vyvanse, Focalin, DIHYDROCODEINE BITARTRATE, PYRILAMINE MALEATE, Pyrilamine, PYRILAMINE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-quillivant-xr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Low Dose Quillivant XR — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low Dose Quillivant XR (Low Dose Quillivant XR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Central nervous system stimulant; amphetamine-class psychostimulant. Area: Psychiatry / Neurology.

marketed Central nervous system stimulant; amphetamine-class psychostimulant Dopamine transporter (DAT); norepinephrine transporter (NET) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Low Dose Quillivant XR (Low Dose Quillivant XR) — Seattle Children's Hospital. Quillivant XR is an extended-release formulation of methylphenidate that increases dopamine and norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Low Dose Quillivant XR TARGET	Low Dose Quillivant XR	Seattle Children's Hospital	marketed	Central nervous system stimulant; amphetamine-class psychostimulant	Dopamine transporter (DAT); norepinephrine transporter (NET)
Vyvanse	LISDEXAMFETAMINE	Takeda	marketed	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	2007-01-01
Focalin	DEXMETHYLPHENIDATE	Novartis	marketed	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	2001-01-01
DIHYDROCODEINE BITARTRATE	DIHYDROCODEINE BITARTRATE		marketed	Central Nervous System Stimulant [EPC]		1983-01-01
PYRILAMINE MALEATE	PYRILAMINE MALEATE		marketed	Central Nervous System Stimulant [EPC]		1973-01-01
Pyrilamine	mepyramine	Impax Labs	marketed	Central Nervous System Stimulant [EPC]	Histamine H1 receptor	1973-01-01
PYRILAMINE	PYRILAMINE		marketed	Central Nervous System Stimulant [EPC]		1973-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Central nervous system stimulant; amphetamine-class psychostimulant class)

Seattle Children's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low Dose Quillivant XR — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-quillivant-xr. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab